AIM ImmunoTech Inc.
AIM
$0.23
$0.00-0.09%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -21.49% | -35.62% | -48.24% | -41.05% | -39.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -21.49% | -35.62% | -48.24% | -41.05% | -39.80% |
| Cost of Revenue | 234.29% | 269.70% | 312.90% | 163.89% | -39.66% |
| Gross Profit | -125.58% | -124.78% | -128.78% | -88.96% | -39.86% |
| SG&A Expenses | -25.97% | -43.97% | -43.38% | -50.08% | -49.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.86% | -41.78% | -41.07% | -47.78% | -47.37% |
| Operating Income | 32.94% | 41.83% | 41.01% | 47.83% | 47.42% |
| Income Before Tax | 11.73% | 12.70% | 19.41% | 34.18% | 42.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.73% | 12.70% | 19.41% | 34.18% | 42.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.73% | 12.70% | 19.41% | 34.18% | 42.36% |
| EBIT | 32.94% | 41.83% | 41.01% | 47.83% | 47.42% |
| EBITDA | 34.99% | 43.64% | 42.69% | 49.16% | 48.64% |
| EPS Basic | 84.09% | 69.83% | 61.38% | 58.04% | 56.64% |
| Normalized Basic EPS | 78.39% | 64.04% | 56.37% | 56.42% | 56.23% |
| EPS Diluted | 84.09% | 69.83% | 61.38% | 58.04% | 56.64% |
| Normalized Diluted EPS | 78.39% | 64.04% | 56.37% | 56.42% | 56.23% |
| Average Basic Shares Outstanding | 887.54% | 312.21% | 187.65% | 100.73% | 33.91% |
| Average Diluted Shares Outstanding | 887.54% | 312.21% | 187.65% | 100.73% | 33.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |